AU2004231211B2 - Compositions comprising a potassium salt active ingredient, including oral compositions for reducing dental nerve and dentin sensitivity comprising a non-menthol flavoring - Google Patents
Compositions comprising a potassium salt active ingredient, including oral compositions for reducing dental nerve and dentin sensitivity comprising a non-menthol flavoring Download PDFInfo
- Publication number
- AU2004231211B2 AU2004231211B2 AU2004231211A AU2004231211A AU2004231211B2 AU 2004231211 B2 AU2004231211 B2 AU 2004231211B2 AU 2004231211 A AU2004231211 A AU 2004231211A AU 2004231211 A AU2004231211 A AU 2004231211A AU 2004231211 B2 AU2004231211 B2 AU 2004231211B2
- Authority
- AU
- Australia
- Prior art keywords
- polydimethylsiloxane
- composition
- fatty acyl
- oral
- potassium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims description 255
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 title claims description 66
- 210000005036 nerve Anatomy 0.000 title claims description 46
- 201000002170 dentin sensitivity Diseases 0.000 title claims description 40
- 229940041616 menthol Drugs 0.000 title claims description 29
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 title claims description 28
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 title claims description 28
- 239000004480 active ingredient Substances 0.000 title description 16
- -1 fatty acid diester Chemical class 0.000 claims description 128
- 239000004094 surface-active agent Substances 0.000 claims description 82
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 67
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 67
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 67
- 239000011734 sodium Substances 0.000 claims description 47
- 229910052708 sodium Inorganic materials 0.000 claims description 45
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 35
- 150000008051 alkyl sulfates Chemical class 0.000 claims description 33
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical group [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 28
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 21
- 159000000000 sodium salts Chemical class 0.000 claims description 19
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 17
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 17
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 16
- 235000010333 potassium nitrate Nutrition 0.000 claims description 16
- 239000004323 potassium nitrate Substances 0.000 claims description 15
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 14
- 239000000194 fatty acid Substances 0.000 claims description 14
- 229930195729 fatty acid Natural products 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 229940008099 dimethicone Drugs 0.000 claims description 13
- 150000003014 phosphoric acid esters Chemical class 0.000 claims description 13
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 12
- 239000008135 aqueous vehicle Substances 0.000 claims description 12
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 12
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 12
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 229960003237 betaine Drugs 0.000 claims description 9
- 150000002190 fatty acyls Chemical group 0.000 claims description 9
- 239000002324 mouth wash Substances 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 230000035945 sensitivity Effects 0.000 claims description 8
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 7
- SUZRRICLUFMAQD-UHFFFAOYSA-N N-Methyltaurine Chemical compound CNCCS(O)(=O)=O SUZRRICLUFMAQD-UHFFFAOYSA-N 0.000 claims description 7
- 150000005690 diesters Chemical class 0.000 claims description 7
- 108010077895 Sarcosine Proteins 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 229940071089 sarcosinate Drugs 0.000 claims description 6
- 229940043230 sarcosine Drugs 0.000 claims description 6
- 229940104261 taurate Drugs 0.000 claims description 6
- 229960003080 taurine Drugs 0.000 claims description 6
- CQAIPTBBCVQRMD-UHFFFAOYSA-L dipotassium;phosphono phosphate Chemical compound [K+].[K+].OP(O)(=O)OP([O-])([O-])=O CQAIPTBBCVQRMD-UHFFFAOYSA-L 0.000 claims description 5
- NNGFQKDWQCEMIO-UHFFFAOYSA-M potassium;hydron;phosphonato phosphate Chemical compound [K+].OP(O)(=O)OP(O)([O-])=O NNGFQKDWQCEMIO-UHFFFAOYSA-M 0.000 claims description 5
- LSKHZZSZLMMIMU-UHFFFAOYSA-K tripotassium;hydron;phosphonato phosphate Chemical compound [K+].[K+].[K+].OP([O-])(=O)OP([O-])([O-])=O LSKHZZSZLMMIMU-UHFFFAOYSA-K 0.000 claims description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 42
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 42
- 239000003599 detergent Substances 0.000 description 38
- 239000000126 substance Substances 0.000 description 25
- 238000009472 formulation Methods 0.000 description 24
- 125000000217 alkyl group Chemical group 0.000 description 21
- 239000004615 ingredient Substances 0.000 description 20
- 159000000001 potassium salts Chemical class 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 229920001296 polysiloxane Polymers 0.000 description 18
- 239000000551 dentifrice Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000000499 gel Substances 0.000 description 16
- 230000002209 hydrophobic effect Effects 0.000 description 15
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 12
- 244000246386 Mentha pulegium Species 0.000 description 11
- 235000016257 Mentha pulegium Nutrition 0.000 description 11
- 235000004357 Mentha x piperita Nutrition 0.000 description 11
- 239000004744 fabric Substances 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- 235000001050 hortel pimenta Nutrition 0.000 description 11
- 210000000214 mouth Anatomy 0.000 description 11
- 229940051866 mouthwash Drugs 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 239000000377 silicon dioxide Substances 0.000 description 9
- 229920001285 xanthan gum Polymers 0.000 description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 8
- ONQDVAFWWYYXHM-UHFFFAOYSA-M potassium lauryl sulfate Chemical compound [K+].CCCCCCCCCCCCOS([O-])(=O)=O ONQDVAFWWYYXHM-UHFFFAOYSA-M 0.000 description 8
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 8
- 239000000600 sorbitol Substances 0.000 description 8
- 235000010356 sorbitol Nutrition 0.000 description 8
- 239000000230 xanthan gum Substances 0.000 description 8
- 235000010493 xanthan gum Nutrition 0.000 description 8
- 229940082509 xanthan gum Drugs 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229940116985 potassium lauryl sulfate Drugs 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000001103 potassium chloride Substances 0.000 description 6
- 235000011164 potassium chloride Nutrition 0.000 description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 6
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 6
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 5
- 150000004673 fluoride salts Chemical class 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000003906 humectant Substances 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229960003975 potassium Drugs 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 235000015497 potassium bicarbonate Nutrition 0.000 description 5
- 239000011736 potassium bicarbonate Substances 0.000 description 5
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 5
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 5
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 235000014749 Mentha crispa Nutrition 0.000 description 4
- 244000024873 Mentha crispa Species 0.000 description 4
- 239000003082 abrasive agent Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 210000004268 dentin Anatomy 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 208000002064 Dental Plaque Diseases 0.000 description 3
- 240000001238 Gaultheria procumbens Species 0.000 description 3
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000233805 Phoenix Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000036372 Sensitivity of teeth Diseases 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- KKWUACQXLWHLCX-UHFFFAOYSA-N hydron;tetradecan-1-amine;chloride Chemical compound Cl.CCCCCCCCCCCCCCN KKWUACQXLWHLCX-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 229940105902 mint extract Drugs 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 108700004121 sarkosyl Proteins 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- MQFYRUGXOJAUQK-UHFFFAOYSA-N 2-[2-[2-(2-octadecanoyloxyethoxy)ethoxy]ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOC(=O)CCCCCCCCCCCCCCCCC MQFYRUGXOJAUQK-UHFFFAOYSA-N 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- ONJPCDHZCFGTSI-NJYHNNHUSA-N CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC(C)C)[C@H]1OC[C@H](O)[C@H]1O Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC(C)C)[C@H]1OC[C@H](O)[C@H]1O ONJPCDHZCFGTSI-NJYHNNHUSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 101000801619 Homo sapiens Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 102100033564 Long-chain-fatty-acid-CoA ligase ACSBG1 Human genes 0.000 description 2
- 235000014435 Mentha Nutrition 0.000 description 2
- 241001072983 Mentha Species 0.000 description 2
- 235000007265 Myrrhis odorata Nutrition 0.000 description 2
- 244000227633 Ocotea pretiosa Species 0.000 description 2
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 2
- 240000004760 Pimpinella anisum Species 0.000 description 2
- 235000012550 Pimpinella anisum Nutrition 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 244000223014 Syzygium aromaticum Species 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 235000010634 bubble gum Nutrition 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000019820 disodium diphosphate Nutrition 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- GYQBBRRVRKFJRG-UHFFFAOYSA-L disodium pyrophosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 2
- 229940038485 disodium pyrophosphate Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000014569 mints Nutrition 0.000 description 2
- 229940074371 monofluorophosphate Drugs 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 description 2
- 229960004025 sodium salicylate Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000007707 Mentha arvensis Species 0.000 description 1
- 235000007421 Mentha citrata Nutrition 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- DIOYAVUHUXAUPX-KHPPLWFESA-N Oleoyl sarcosine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N(C)CC(O)=O DIOYAVUHUXAUPX-KHPPLWFESA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- BSKALNOLPVKFND-KTKRTIGZSA-N [(z)-hexadec-7-enyl] hydrogen sulfate Chemical compound CCCCCCCC\C=C/CCCCCCOS(O)(=O)=O BSKALNOLPVKFND-KTKRTIGZSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 1
- 238000004851 dishwashing Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940091249 fluoride supplement Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940071088 methyl cocoyl taurate Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940094025 potassium bicarbonate Drugs 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 229940093928 potassium nitrate Drugs 0.000 description 1
- 229940093916 potassium phosphate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- BFDWBSRJQZPEEB-UHFFFAOYSA-L sodium fluorophosphate Chemical compound [Na+].[Na+].[O-]P([O-])(F)=O BFDWBSRJQZPEEB-UHFFFAOYSA-L 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 229950005425 sodium myristyl sulfate Drugs 0.000 description 1
- BCISDMIQYBCHAT-UHFFFAOYSA-M sodium;2-(dodecanoylamino)ethanesulfonate Chemical compound [Na+].CCCCCCCCCCCC(=O)NCCS([O-])(=O)=O BCISDMIQYBCHAT-UHFFFAOYSA-M 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- IZWPGJFSBABFGL-GMFCBQQYSA-M sodium;2-[methyl-[(z)-octadec-9-enoyl]amino]ethanesulfonate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)N(C)CCS([O-])(=O)=O IZWPGJFSBABFGL-GMFCBQQYSA-M 0.000 description 1
- MWZFQMUXPSUDJQ-KVVVOXFISA-M sodium;[(z)-octadec-9-enyl] sulfate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCCOS([O-])(=O)=O MWZFQMUXPSUDJQ-KVVVOXFISA-M 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 description 1
- WFRKJMRGXGWHBM-UHFFFAOYSA-M sodium;octyl sulfate Chemical compound [Na+].CCCCCCCCOS([O-])(=O)=O WFRKJMRGXGWHBM-UHFFFAOYSA-M 0.000 description 1
- UPUIQOIQVMNQAP-UHFFFAOYSA-M sodium;tetradecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOS([O-])(=O)=O UPUIQOIQVMNQAP-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940062627 tribasic potassium phosphate Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
S&F Ref: 497682D1
AUSTRALIA
PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT Name and Address of Applicant Actual Inventor(s): Address for Service: Invention Title: Pfizer Products Inc., of Eastern Point Road, Groton, Connecticut, 06340, United States of America Andrew R. Gallopo Dennis George Anthony Nelson Spruson Ferguson St Martins Tower Level 31 Market Street Sydney NSW 2000 (CCN 3710000177) Compositions comprising a potassium salt active ingredient, including oral compositions for reducing dental nerve and dentin sensitivity comprising a non-menthol flavoring The following statement is a full description of this invention, including the best method of performing it known to me/us:- 5845c COMPOSITIONS COMPRISING A POTASSIUM SALT ACTIVE INGREDIENT, INCLUDING ORAL COMPOSITIONS FOR REDUCING DENTAL NERVE AND DENTIN SENSITIVITY O COMPRISING A NON-MENTHOL FLAVORING z Field of the Invention The present invention relates to detergent compositions useful in the healthcare and hard surface and fabric cleaning fields.
Background of the Invention C Sodium alkylsulfate surfactants, sodium lauryl sulfate (SLS), are generally not t' 10 substantially compatible with compounds that contain potassium because an insoluble potassium alkyl sulfate precipitate forms when the sodium alkylsulfate is combined with a potassium salt. While the solubility of SLS in water is about 10% on a gram per gram basis, C experiments indicate that the solubility of potassium lauryl sulfate is less than approximately 0.02%.
Thus, many aqueous compositions which contain SLS cannot contain a potassium salt which might otherwise be useful as an active ingredient. If the potassium salt and SLS do coexist in a composition, the usefulriess of that potassium salt is not being optimized since a portion of the potassium ion of the salt is being occupied in the insoluble potassium lauryl sulfate precipitate. Alternatively, if a potassium salt is a required ingredient in a composition, nonionic surfactants can be used instead of SLS to avoid a potassium lauryl sulfate precipitation. However, such nonionic surfactants are in many instances not as effective as SLS as wetting or cleaning agents. For example, oral care compositions which contain nonionic surfactants instead of SLS are not as effective in removing dental plaque. It would thus be beneficial in the healthcare and surface and fabric cleaning fields if SLS could be combined with a potassium salt without forming an insoluble potassium lauryl sulfate precipitate.
Numerous potassium salts are useful in detergent compositions. Potassium pyrophosphate salts, for example, can have detergent building activity in detergent compositions that comprise a wetting agent such as SLS. However, the detergent building activity of the potassium pyrophosphate salt in such compositions may not be optimal due to the formation of the potassium lauryl sulfate precipitate described above. For example, U.S.
Patent 5,338,538 to Tricca et aL. relates to liquid compositions for loosening and removing plaque that comprise SLS and a detergent builder selected from dialkali metal pyrophosphate salts, tetraalkali metal pyrophosphate salts, and mixtures thereof. The preferred pyrophosphate salts are disodium pyrophosphate and tetrasodium pyrophosphate. It may be useful to be able to add potassium pyrophosphate salts to compositions such as those referred to in U.S. patent 5,338,538. This is because potassium pyrophosphate salts can be more soluble than sodium pyrophosphate salts and a higher concentration of pyrophosphate in solution could, thus, be achieved. Also, replacing all or some sodium pyrophosphate salt 2 O with potassium pyrophosphate would reduce the sodium content of the oral composition, which some consumers may find preferable.
SFurthermore, many potassium salts possess therapeutic activities which are useful in 00 healthcare compositions. For example, several potassium salts are believed to possess activity in reducing dental nerve and/or dentin sensitivity. Such potassium salts could therefore be included in oral compositions designed for the treatment of sensitive teeth and gums. U.S. Patent 4,751,072 to Kim, for example, relates to a method for reducing sensory nerve activity in hypersensitive teeth and for desensitizing hypersensitive dentin N. that involves applying a potassium salt selected from potassium bicarbonate and 0o potassium chloride. Also, U.S. Patent 5,403,577 to Friedman refers to a sustained-release Noral composition for treating and preventing dental hypersensitivity comprising an antihypersensitivity agent selected from a group of active ingredients including potassium nitrate, potassium bicarbonate, and potassium chloride. Moreover, potassium ions are believed to block nerve conduction in vitro (Peackock, and Orchardson, 1995, J.
Dent. Res. 74(2):634-641). However, any SLS present in such a sensitivity composition comprising a potassium salt may result in the formation of the aforementioned insoluble potassium lauryl sulfate precipitate.
Summary of the Invention: According to a first aspect of the present invention, there is provided an oral mouthrinse composition for reducing nerve sensitivity comprising: a) from about 0.01% by weight to about 5% by weight of an orally-acceptable, soluble potassium salt; b) from about 0.01% by weight to about 10% by weight of a sodium (C 8
-C
24 alkylsulfate; c) from about 0.01% by weight to about 20% by weight of an orally-acceptable polar surfactant, said surfactant selected from the group consisting of (C 6
-C
30 fatty acid mono or diester of ethoxylated sorbitan, a (C 6
-C
3 0 fatty acid diester of polyethylene glycol, a sodium salt of a (C 6
-C
3 0 fatty acyl sarcosinate, a (C 6
-C
3 0 fatty acyl ester of sarcosine acid, a sodium salt of a (C 6
-C
30 fatty acyl taurate, a sodium salt of a (C 6
-C
30 fatty acyl methyltaurate, a (C 6
-C
3 0 fatty acyl ester oftaurine, a (C 6
-C
30 fatty acyl ester of methyltaurine acid, a (C 6
-C
30 fatty acyl betaine, a (C 6
-C
30 fatty acyl quaternary ammonium chloride, dimethicone copolyols, polydimethylsiloxane phosphate esters, polydimethylsiloxane copolyol phosphate esters, polydimethylsiloxane phosphobetaines, polydimethylsiloxane copolyol phosphobetaines, polydimethylsiloxane taurates, 677659- hjg 0polydimethylsiloxane copolyol taurates, acetylated polydimethylsiloxane copolyols, and polydimethylsiloxane quaternium compounds, polydimethylsiloxane copolyol quaterium Scompounds; and 00 d) an orally-acceptable aqueous vehicle comprising from about 50% to about 85% water; wherein the potassium salt is dissolved in the composition and wherein the Smolar ratio of the surfactant of to the sodium (C 8
-C
2 4 alkylsulfate is greater than or Sequal to about 1:1 such that when are dissolved in the resultant Scomposition is clear.
N According to a second aspect of the present invention, there is provided an oral composition in the form of a rinse for reducing dental nerve and/or dentin sensitivity Ncomprising: a) from about 0.1% to about 5% potassium nitrate; b) from about 0.02% to about 2% SLS; c) from about 0.1% to about 20% by weight of an orally-acceptable polar surfactant, said surfactant selected from the group consisting of a (C 6
-C
3 0 fatty acid mono diester of ethoxylated sorbitan, a (C 6
-C
30 fatty acid diester of polyethylene glycol, a sodium salt of a (C 6
-C
30 fatty acyl sarcosinate, a (C 6
-C
30 fatty acyl ester of sarcosine acid, a sodium salt of a (C 6
-C
30 fatty acyl taurate, a sodium salt of a (C 6
-C
30 fatty acyl methyltaurate, a (C 6
-C
30 fatty acyl ester of taurine, a (C 6
-C
30 fatty acyl ester of methyltaurine acid, a (C 6
-C
30 fatty acyl betaine, a (C 6
-C
30 fatty quaternary ammonium chloride, dimethicone copolyols, polydimethylsiloxane phosphate esters, polydimethylsiloxane copolyol phosphate esters, polydimethylsiloxane phosphobetaines, polydimethylsiloxane, copolyol phosphobetaines, polydimethylsiloxane taurates, polydimethylsiloxane copolyol taurates, acetylated polydimethylsiloxane copolyols, and polydimethylsiloxane quaternium compounds, polydimethylsiloxane copolyol quaternium compounds; and d) an orally-acceptable aqueous vehicle comprising from about 50% to about water; wherein the potassium salt is dissolved in the composition and wherein the molar ratio of the surfactant of to the sodium (C 8
-C
2 4 alkylsulfate is greater than or equal to about 1:1 such that when are dissolved in the resultant composition is clear.
According to a third aspect of the present invention, there is provided an oral composition in the form of a rinse for removing or loosening plaque and/or stains from dental surfaces comprising: 677659-1hjg a) from about 0.1% to about 5% of a potassium salt selected from the group consisting of dipotassium pyrophosphate, tetrapotassium pyrophosphate, tripotassium Spyrophosphate, monopotassium pyrophosphate, and combinations thereof; 00 b) from about 0.02% to about 2% SLS; c) from about 0.1% to about 20% by weight of an orally-acceptable polar Ssurfactant, said surfactant selected from the group consisting of a (C 6
-C
30 fatty acid mono or diester of ethoxylate sorbitan, a (C 6
-C
30 fatty acid diester of polyethylene glycol, a sodium salt of a (C 6
-C
3 0 fatty acyl sarcosinate, a (C 6
-C
30 fatty acyl ester of sarcosine acid, a sodium salt of a (C 6
-C
30 fatty acyl taurate, a sodium salt of a (C 6
-C
30 0o fatty acyl methyltaurate, a (C 6
-C
30 fatty acyl ester of taurine, a (C 6
-C
30 fatty acyl ester of C methyltaurine acid, a (C 6
-C
3 0 fatty acyl betaine, a (C 6
-C
30 fatty acyl quaternary ammonium chloride, dimethicone copolyols, polydimethylsiloxane phosphate esters, polydimethylsiloxane copolyol phosphate esters, polydimethylsiloxane phosphobetaines, polydimethylsiloxane copolyol phosphobetaines, polydimethylsiloxane taurates, polydimethylsiloxane copolyol taurates, acetylated polydimethylsiloxane copolyols, and polydimethylsiloxane quaternium compounds, polydimethylsiloxane copolyol quaternium compounds; and d) an orally-acceptable aqueous vehicle comprising from about 50% to about water; wherein the potassium salt is dissolved in the composition and wherein the molar ratio of the surfactant of to the sodium (C 8
-C
24 alkylsulfate is greater than or equal to about 1:1 such that when and are dissolved in the resultant composition is clear.
The subject invention provides an oral composition comprising: a) from about 0.01% by weight to about 20% by weight of an active ingredient which is an orally-acceptable, soluble potassium salt; b) from about 0.01% by weight to about 10% by weight of a sodium (C 8
-C
24 alkylsulfate; c) from about 0.01% by weight to about 20% by weight of an orally-acceptable polar surfactant, said surfactant comprising a hydrophobic portion selected from a (C 6
C
30 alkyl group and a polymeric silicone group; and d) an orally-acceptable aqueous vehicle; wherein the molar ratio of the surfactant of to the sodium (C 8
-C
24 alkylsulfate of is greater than or equal to about 1:1.
The subject invention further provides an oral composition as recited above, suitable for loosening or removing plaque and/or stains present on dental surfaces, 2c rwherein the soluble potassium salt of the composition comprises a potassium pyrophosphate salt in an amount effective, optionally in combination with other Spyrophosphate salts, to remove or loosen plaque and/or stains when the composition is 00 orally applied to a dental surface.
The subject invention further provides oral composition as recited above, suitable for reducing dental nerve and/or dentin sensitivity, wherein the soluble potassium salt of the composition comprises a potassium salt capable of reducing dental nerve and/or dentin sensitivity in an amount effective to reduce dental nerve and/or dentin sensitivity when the o composition is orally applied to a dental surface.
Z The subject invention further provides an oral composition for reducing dental nerve and/or dentin sensitivity comprising an effective amount of an ingredient that possesses activity in reducing dental nerve and/or dentin sensitivity, an orally-acceptable vehicle, and a flavoring that does not contain a substantial amount of menthol, said flavoring in an amount effective to provide flavor to said composition.
The subject invention further provides a mint flavoring that does not comprise a substantial amount of menthol, said mint flavoring being either a dementholated natural mint extract or a synthetic blend.
The subject invention further provides an aqueous detergent composition comprising an effective amount of an active ingredient that is a soluble potassium salt, a sodium (C 8
-C
24 alkylsulfate in an amount effective to remove or loosen debris and/or stains from a surface, and a polar surfactant, said surfactant comprising a hydrophobic portion selected from a (C6- C30) alkyl group and a polymeric silicone group, wherein the molar ratio of the surfactant to the sodium (C 8
-C
24 alkylsulfate is greater than or equal to about 1:1.
The subject invention further provides a method for inhibiting the formation of a potassium alkylsulfate precipitate in an aqueous composition comprising a soluble potassium salt and a sodium (C 8
-C
24 alkylsulfate, which method comprises including a polar surfactant in said composition in an amount of about equal to or greater than the amount of sodium (C8-
C
24 alkylsulfate in the composition, which polar surfactant comprises a hydrophobic portion selected from the group consisting of a (C 6 -C30) alkyl group and a polymeric silicone group.
The subject invention further provides a method of loosening and/or removing dental plaque and/or stains while simultaneously reducing dental nerve and/or dentin sensitivity in an oral cavity of a mammal, comprising administering to the oral cavity of said mammal an effective amount of an oral composition as described herein.
The subject invention further provides a method of loosening and/or removing dental plaque and/or stains in an oral cavity of a mammal, comprising administering to the oral cavity of said mammal an effective amount of an oral composition as described herein.
The subject invention further provides a detergent composititn as described herein, suitable for loosening anrid/or removing dirt, debris, and/or stains from skin and/or hair.
The subject invention further provides a method of loosening and/or removing dirt, debris, and/or stains from skin or hair, comprising administering to said skin or hair an amount of a composition as described herein effective in removing or loosening dirt, debris, or stains.
The subject invention further provides a detergent composition as described herein, suitable for loosening and/or removing dirt, debris, and/or stains from a hard surface and/or a fabric.
The subject invention further provides a method of loosening or removing dirt, debris, and/or stains from a hard surface or a fabric, comprising administering to said hardsurface or fabric an amount of a composition as described herein effective in removing or loosening dirt, debris, or stains.
Detailed Description Of the Invention: The subject invention provides an oral composition Which comprises a sodium alkylsulfate and a potassium salt, said compositions further comprising a surfactant in order to inhibit the formation of a potassium lauryl sulfate precipitate.
The subject invention can, however, be applied to any composition, not just oral compositions, that contains both a sodium (C 8
-C
24 alkylsulfate and a potassium salt. For example, the subject invention can also have applications in hair and/or body shampoos, bubble baths, shaving creams, dishwashing detergents, upholstery cleaners (such as, fabric, vinyl, and leather cleaners), carpet detergents, laundry detergents, and hard surface cleaners.
All of the aforementioned compositions possess detergent properties, either as a primary function (as in the case of, for example, a shampoo) or a secondary function (as in the case of, for example, a shaving cream), and all can use a sodium alkylsulfate, such as SLS, as a wetting agent. Therefore, any such composition could benefit from the present invention, which permits the inclusion of a soluble potassium salt, e.g. a potassium pyrophosphate salt, that can impart desirable characteristics to said composition, for example enhanced detergent capability.
Accordingly, the subject invention also provides a detergent composition comprising an effective amount of a soluble potassium salt, a sodium (C 8
-C
2 4 alkylsulfate, and a polar surfactant, said surfactant comprising a hydrophobic portion selected from the group consisting of a (C 8 -C30) alkyl group and a polymeric silicone group, wherein the molar ratio of the surfactant to the sodium (C 8
-C
2 4 alkylsulfate is greater than or equal to about 1:1. The subject invention further provides a method for inhibiting the formation of a potassium alkylsulfate precipitate from forming in a composition comprising a soluble potassium salt and a sodium (C 8
-C
2 4 alkylsulfate, which method comprises including a polar surfactant in said composition in an amount of about equal to or greater than the amount of sodium (C 8
-C
24 alkylsulfate in the composition, which polar surfactant comprises a hydrophobic portion selected from a (C 6
-C
3 0 alkyl group and a polymeric silicone group.
As used herein, the term "detergent composition" refers to a composition which has as either a primary or a secondary function the ability to loosen or remove debris and/or stains from a surface. In one embodiment, a detergent composition of the present invention jis an oral composition.
As used herein, unless otherwise indicated, the term "oral composition" refers to a detergent composition, as defined above (having a detergent property as either a primary or secondary function), useful for oral care, including compositions for the care of teeth and/or gums. Examples of forms the detergent compositions of the present invention can have include gels, pastes, and liquids (oral rinses). The term "gel" refers to a visually-clear semisolid composition. Gels according to this invention can have various viscosities. One of ordinary skill can also formulate the compositions of the present invention into other forms that are known in the art. Examples of other forms include, but are not limited to, creams, tablets, and granulations.
Oral compositions of the present invention include, for example, dentifrices. A dentifrice is a composition, in a form such as a paste or gel, which composition comprises an abrasive, and which composition is useful for removing and/or loosening plaque, debris and/or stains from teeth and gums. Other oral compositions of the invention include oral rinses, for example mouthwashes for treating oral malodor and rinses that have as their primary function detergent properties for removal and/or loosening of plaque. "Oral rinses" are to be distingushed from dentifrices in that oral rinses do not include an abrasive.
The amounts of ingredients and the solubilities recited as percentages throughout this application, unless otherwise indicated, refer to the amount by weight of such ingredient or solute compared to the total weight of the composition containing the ingredient or solute. For example, a composition comprising from about 0.01% by weight to about 20% by weight of an orally-acceptable polar surfactant comprises from about one ten-thousandth to about two tenths of a gram of the polar surfactant per gram of the total composition from about one one-hundredth to about 20 grams of the polar surfactant per 100 grams of total composition).
A composition of the present invention comprises a soluble potassium salt as an active ingredient. The term "active ingredient" refers to, unless otherwise indicated, any substance that possesses a therapeutic, hygienic or cosmetic activity in a detergent composition (for example an oral composition), or possesses an activity that enhances the aesthetic or sensory properties of the detergent composition, or possesses activity that enhances the detergent properties of the detergent composition. For example, certain potassium salts, such as potassium sorbate, possess bacteriostatic activity and can therefore be an active ingredient because they are useful in a detergent composition as a preservative.
As another example, certain potassium salts, such as potassium pyrophosphate salts, have mineral-chelating activity in water and can serve as an active ingredients because they behave as detergent builders, enhancing the ability of the sodium alkylsulfate in the detergent composition to remove and loosen debris, such as plaque, and/or stains. Other potassium salts, such as potassium nitrate and potassium chloride, can be an active ingredient because they can reduce dental nerve and/or dentin sensation. Still other potassium salts, for example potassium phosphate, can be an active ingredient because they can buffer a detergent composition to a selected pH, for example a pH of about 7. Other potassium salts having particular properties known in the art can be selected as an active ingredient, and Scompositions comprising such potassium salts are part of the subject invention.
Z If a composition of the present invention is to be applied to the skin and/or hair of a living animal, including a human, then the potassium salt therein must be acceptable for application without harmful side effects when used as intended. Likewise, if the composition is for oral use, then the potassium salt therein must be orally-acceptable, i.e. acceptable for use by humans or other animals in the oral cavity without harmful side effects. Orally- Cacceptable potassium salts and potassium salts that are acceptable for application to skin and/or hair of living animals can be determined by those of ordinary skill in the art.
The term "orally applied" as used herein, unless otherwise indicated, means application to the oral cavity of a living animal. "Oral application" includes, but is not limited to, brushing the oral cavity and/or teeth in the oral cavity, rinsing the oral cavity and gargling, and spraying into the oral cavity.
A "soluble potassium salt", for purposes of this application and unless otherwise indicated, is any organic or inorganic potassium salt that is soluble in an aqueous solution.
Preferably, the soluble potassium salt is any potassium salt that has a solubility of greater than or equal to about 5% in water, meaning that an aqueous composition of the potassium salt (consisting solely of water and the potassium salt) can contain at least about .05 grams of the potassium salt, if not more, in solution. Thus, one hundred grams of an aqueous solution consisting of a potassium salt that is at least about 5% soluble in water contains at least about grams of the potassium salt and at most about 95 grams of water.
The active ingredient is present in the compositions of the present invention in an "effective amount", which means that the ingredient, the soluble potassium salt, is present in the composition in an amount that is at least sufficient to provide the activity for which the potassium salt has been selected. An effective amount can be determined by one of ordinary skill in the art, for example by preparing a series of pre-formulations, each comprising a different amount of the potassium salt, testing each pre-formulation for the activity of the potassium salt, and determining the minimum amount of the potassium salt required to provide the desired activity. Generally, the amount of soluble potassium salt effective for a hard surface or fabric cleaner is from about 0.1% to about 50%, and for a healthcare composition is from about 0.1% to about Some specific examples of orally-acceptable, soluble potassium salts that can be used as an active ingredient in an oral composition of the present invention include potassium pyrophosphate salts, such as dipotassium pyrophosphate, tetrapotassium pyrophosphate, tripotassium pyrophosphate, and monopotassium pyrophosphate. Pyrophosphate salts have activity as detergent builders and thus are useful in loosening and removing plaque and/or stains present on dental surfaces. A composition of the present invention can comprise a r combination of pyrophosphate salts, for example a combination of potassium pyrophosphate salts, each of which has activity as a detergent builder. Oral compositions of the present Z invention can furthermore optionally comprise potassium pyrophosphate salts in combination with other pyrophosphate salts, such as, for example, disodium pyrophosphate or tetrasodium pyrophosphate, to remove or loosen plaque and/or stains when the composition is orally applied to a dental surface.
_Other specific examples of potassium salts that can be used in an oral composition of K the present invention are potassium salts that are active in reducing dental nerve and/or M dentin sensitivity. Potassium salts that possess activity in reducing dental nerve and/or dentin sensitivity are known in the art, and any such potassium salt is useful in the present invention.
Examples of potassium salts that are active in reducing dental nerve and/or dentin sensitivity C include, but are not limited to, potassium nitrate, potassium citrate, potassium chloride, potassium oxalate, potassium bicarbonate, potassium phosphate, monobasic potassium phosphate, dibasic potassium phosphate, tribasic potassium phosphate, and potassium pyrophosphate salts. Mixtures of such salts can be used in the present invention. In a preferred embodiment, the potassium salt capable of reducing dental nerve and/or dentin sensitivity is potassium nitrate.
A composition of the present invention can comprise a mixture of soluble potassium salts. Each potassium salt in the mixture can have the same or similar activity (for example, they each can have activity as a detergent builder, enhancing removal or loosening of debris and/or stains) or potassium salts in the mixture can have different activities (for example, one salt can have activity as a detergent builder and another salt in the mixture can have activity in reducing dental nerve sensation).
The amount of the soluble potassium salt ranges preferably from about 0.01% by weight to about 20% by weight of a healthcare composition of the present invention, preferably from about 0.1% by weight to about 50% by weight of a hard surface cleaner of the present invention, and preferably from about 0.1% by weight to about 50% by weight of a fabric cleaner composition of t c present inw-ition. If the composition is a dentifrice, a preferred amount of potassium salt in such dentifrice is from about 1% to about 10%. If the composition is an oral rinse, a preferred amount of potassium salt in such an oral rinse is from about 0.1% to about In specific oral compositions of the present invention for removing and loosening plaque and stains, a potassium pyrophosphate salt is present in the composition in an amount effective, optionally in combination with other pyrophosphate salts as described above, to provide at least about more particularly from about 0.3% to about by weight P 2 07 4 based on the weight of the total composition. In order to provide this amount of P 2 07 4 compositions of this invention for loosening or removing plaque and/or stains from dental Ssurfaces preferably contain from about 0.02% by weight to about 1% by weight potassium Spyrophosphate salt based on the weight of the total composition.
Z Regarding the sodium alkylsulfate ingredient of the compositions of the present invention, the term "sodium (C 8
-C
24 alkylsulfate" refers to any sodium (C 8
-C
2 4 alkylsulfate or mixture of sodium (C 8
-C
2 4 alkylsulfates. The term "alkyl", as used herein, refers to any hydrocarbon, either saturated or unsaturated, and either straight, branched, or cyclic.
Reference to a specific sodium (C 8
-C
24 alkylsulfate, such as SLS, includes both the pure Ssodium
(C
8
-C
2 4 alkylsulfate as well as various grades of the sodium (C 8
-C
24 alkylsulfate Swhich contain relatively small amounts of different sodium (C 8
-C
24 alkylsulfates. For N 10 example, the term "SLS" includes both compositions of pure SLS as well as various grades of SSLS which can contain other sodium alkylsulfates that can have generally from 10 to 14 C1 carbons their alkyl portion and that can further have one or more unsaturated bonds in their alkyl portions. Sodium (C 8
-C
24 alkylsulfates, such as SLS, are useful as wetting agents, loosening or removing debris and/or stains, in detergent compositions. When the sodium (C 8
C
24 alkylsulfate is free from interaction with a potassium salt ingredient, as is provided by the present invention, a greater amount of debris and stain removal can be obtained. Examples of sodium (C 8
-C
24 alkylsulfates which are useful in the present invention include, but are not limited to, SLS, sodium myristyl sulfate, sodium palmityl sulfate, sodium stearyl sulfate, sodium palmitoleyl sulfate, sodium oleyl sulfate, sodium capryl sulfate, and sodium caprylyl sulfate. The aforementioned sodium (C 8
-C
24 alkylsulfates comprise 12, 14, 16, 18, 16 (with one unsaturated carbon-carbon bond), 18 (with one unsaturated carbon-carbon bond), and 8 carbons, respectively. An example of a sodium alkylsulfate having 24 carbons which can be used in the subject invention is sodium nervonyl acid. Preferably, the compositions of the subject invention comprise SLS.
Preferably, the amount of sodium (C 8
-C
24 alkylsulfate in a composition of the present invention is from about 0.01% to about 10% by weight of the composition for a healthcare composition, from about 0.1% to about 50% by weight for a hard surface cleaner, and from about 0.1 to about 50% for a fabric cleaner composition. The amount of sodium (C 8
-C
24 alkylsulfate of a dentifrice of the subject invention is preferably from about 0.1% to about by weight of the composition. For an oral rinse, the amount of the sodium (C 8
-C
24 alkylsulfate ingredient is preferably from about 0.02% by weight to about 2% by weight of the composition. More preferably for a hard surface cleaner, the amount is from about 1% to about 50%, and more preferably for a fabric cleaner from about 1% to about The polar surfactant used in the compositions of the present invention can be any polar surfactant that comprises a hydrophobic portion selected from the group consisting of a
(C
8 -Cao) alkyl group, wherein "alkyl" is as defined above, and a polymeric silicone group. If the composition is for oral use or for application to skin and/or hair of a living animal, then the C"1 surfactant must not cause harmful side effects to the animal when used as intended.
Determination of surfactants acceptable for such uses is known in the art. A "polar" surfactant Z for purposes of this invention is a surfactant that comprises a hydrophilic group and a hydrophobic group. Polar surfactants can be anionic, cationic, nonionic or amphoteric. One of ordinary skill in the art can determine whether a surfactant is polar.
A "polymeric silicone group" is any group that comprises repeating units which comprise a silicone atom. In a preferred embodiment, a polymeric silicone group comprises cl repeating -Si(R 1
)(R
2 units, wherein R' and R 2 of each unit is independently the same or C different, and wherein each -Si(R')(R 2 unit in the polymeric silicone group can have the same or different R 1 and/or R 2 groups, R 1 and R 2 each being a (C 1
-C
6 alkyl. Preferably each O R 1 and R 2 in a polymeric silicone group is methyl or ethyl. More preferably, each R 1 and R 2 is Nc a methyl.
Polar surfactants which comprise a hydrophobic portion which is a polymeric silicone group can include, but are not limited to, dimethicone copolyols ethoxylated and/or propoxylated polydimethylsiloxane polymers) and derivatives thereof wherein the ethoxylated/propoxylated portion of the compounds is derivatized such as polydimethylsiloxane phosphate esters, polydimethylsiloxane phosphobetaines, polydimethylsiloxane taurates, acetylated polydimethylsiloxane copolyols, and polydimethylsiloxane quaternium compounds. Surfactants comprising a polymeric silicone group are also described, among other places, in Imperante, J. et al., 1994, Cosmetics Toiletries Vol. 108, No. 4, p. 79, and Imperante, J. et al., 1994, Cosmetics Toiletries Vol.
109, No. 3, p. 81, which are hereby incorporated by reference in their entireties.
Some specific examples of derivatized polydimethylsiloxane copolyols are sodium dimethicone copolyol acetyl methyltaurate, e.g. PECOSILTM DCT (Phoenix Chemical, Inc., Somerville, NJ); dimethicone copolyol myristyl ammonium chloride, e.g. PECOSILM (Phoenix Chemical, Inc.); and dimethicone copolyol phosphate, e.g. PECOSILTM PS-100, PECOSIL PS-150, and PECOSIL T PS-200, from Phoenix Chemical, Inc., and SILPHOSTM A100 (Siltech, Norcross, Georgia). As discussed above, other polydimethylsiloxane copolyols are known in the art and can be used in the present invention.
In another embodiment, the polar surfactant comprises a hydrophobic portion comprising a (C 6 -C3o) alkyl group. The (C 6 -Cso) alkyl group can be saturated or unsaturated.
Polar surfactants that comprise a hydrophobic portion comprising a (C 6 -Cso) alkyl group can be determined by one of ordinary skill in the art. Examples of polar surfactants that comprise a hydrophobic portion comprising a (C 6
-C
30 alkyl group include, but are not limited to, (C 6
C
30 fatty acid mono and diesters of ethoxylated sorbitan such as PEG-40 diisostearate (e.g.
EMSORB
M 2726 PEG-40 Sorbitan Diisostearate (Henkel Corporation (Gulph Mills, PA)), PEG-2 sorbitan isostearate, and PEG-40 sorbitan laurate; (C 6 -C0o) fatty acid diesters of rc polyethylene glycol such as PEG-175 distearate and PEG-150 distearate LIPOPEGT S6000-DS (Lipo Chemicals Inc. (Paterson, New Jersey)); sodium salts of (C6-C3) fatty acyl Z sarcosinates such as sodium lauroyl sarcosinate HAMPOSYLTM L-30 (Hampshire (Lexington, Massachusetts)) and sodium cocoyl sarcosinate HAMPOSYLTM (Hampshire); (C 6 -C3o) fatty acyl esters of sarcosine acid such as lauroyl sarcosine
HAMPOSYL
T M L (Hampshire) and oleoyl sarcosine HAMPOSYLTM O (Hampshire)); Ssodium salts of (C6-Cso) fatty acyl taurates and methyltaurates such as sodium lauroyl taurate, Ssodium methyl cocoyl taurate a surfactant from the TAURANOL T M WS series (Finetex m Inc., Elmwood Park, New Jersey)), and sodium methyl oleoyl taurate a surfactant from the TAURANOL T M M series (Finetex (C 6 -C30) fatty acyl esters of taurine and methyltaurine acid; (C 6
-C
3 0 fatty acyl betaines such as cocamidopropyl betaine r" TEGOTM Betaine ZF and TEGO T M Betaine E (both of Goldschmidt Chemical Corp., Hopewell, Virginia)); and (C 6 -C30) fatty acyl quaternary ammonium chlorides such as dimethicone copolyol myristyl ammonium chloride PECOSILTM SM-40, supra). "PEG" in the foregoing examples and throughout this application is an abbreviation for "polyethylene glycol". Other polar surfactants which comprise a (C 6
-C
30 alkyl group can be determined by those of ordinary skill in the art.
In general, polar surfactants that comprise a hydrophobic portion selected from the group consisting of a (C 6
-C
3 0 alkyl group and a polymeric silicone group can be found in texts recognized in the art such as The CTFA International Cosmetic Ingredient Dictionary (Cosmetics Tioleteries and Fragrances Association (Washington which is hereby incorporated by reference in its entirety.
The following procedure can, moreover, be used to screen surfactants, such as those ascertained from The CTFA International Cosmetic Ingredient Dictionary, above, for use in inhibiting formation of a potassium lauryl sulfate salt according to the present invention. The procedure is based on a three part system of surfactant, TKPP (tetrapotassium pyrophosphate), and SLS in water. The surfactant to be tested is weighed out into 250 ml beakers in increasing increments of 0.5g: 0.5g, 1.0g, 2.0g, 2.5g, etc. 90 ml of a TKPP solution is then added and the solution stirred to dissolve the surfactant. (If the surfactant being tested is itself not soluble in the TKPP solution upon visual inspection, i.e. if the solution appears turbid or a precipitate is observed, then other solvents, such as alcohol, can be included in each beaker to dissolve the surfactant). 10 ml of 4.0% SLS solution is then added with stirring. Since this is a ten fold dilution, the final concentration of SLS in the beaker is The concentration of surfactant in each beaker is deemed equal to the number of grams of surfactant in each beaker, without taking into account the concentration of the surfactant as originally added to the beaker. (Each surfactant is often tested as a concentrate). The series of solutions is allowed to stand for at least four hours. The solution cK1 with the lowest concentration of surfactant that is clear is then designated the typical effective concentration. The typical effective concentration of the pure surfactant can then be Z calculated by multiplying the experimentally-determined typical effective concentration by the actual percentage of surfactant in the originally-added surfactant concentrate.
In a specific embodiment, a composition of the present invention is an oral composition for reducing dental nerve and/or dentin sensitivity in the form of a dentifrice, for example a paste or a gel. Such a composition can comprise potassium nitrate in an amount effective to reduce dental nerve and/or dentin sensitivity when the composition is orally Mc, applied to a dental surface, preferably also including a soluble fluoride salt or a soluble monofluorophosphate salt in an amount effective to prevent cavities.
In another embodiment, a composition of the present invention is an oral composition (Ni for removing or loosening plaque and/or stains from dental surfaces in the form of an oral rinse, such as a prebrushing rinse, or in the form of a dentifrice.
A preferred dentifrice of the present invention is in the form of a gel, a "liquid gel" being especially preferred. A liquid gel refers to a gel, as defined above, of low viscosity rendering it suitable for rinsing.
An oral rinse of the present invention is preferably in the form of a liquid gel or of a liquid.
A specific dentifrice of the present invention for reducing dental nerve and/or dentin sensitivity comprises: from about 1% to about 10% potassium nitrate; from about 0.1% to about 5% SLS; from about 0.1% to about 20% by weight of an orally-acceptable polar surfactant, said surfactant comprising a hydrophobic portion selected from the group consisting of a (C 6 C30) alkyl group and a polymeric silicone group; from about 10% to about 60% by weight of an abrasive silica; an effective amount of a soluble fluoride salt; and an orally-acceptable aqueous vehicle; wherein the molar ratio of the surfactant of to SLS of is greater than or equal to about 1:1.
Another specific dentifrice of the present invention is in the form of a gel and is especially useful for removing or loosening plaque and/or stains from dental surfaces. This dentifrice comprises: from about 1% to about 10% of a soluble potassium salt selected from the group consisting of dipotassium pyrophosphate, tetrapotassium pyrophosphate, tripotassium pyrophosphate, monopotassium pyrophosphate, and combinations thereof; from about 0.1% to about 5% SLS; c~ from about 0.1% to about 20% by weight of an orally-acceptable polar surfactant, Osaid surfactant comprising a hydrophobic portion selected from the group consisting of a (C 6 0 z C3) alkyl group and a polymeric silicone group; from about 10% to about 60% by weight of an abrasive silica; an effective amount of a soluble fluoride salt; and an orally-acceptable aqueous vehicle; _wherein the molar ratio of the surfactant of to SLS of is greater than or equal to about 1:1.
Mc, A specific oral rinse of the present invention for reducing dental nerve and/or dentin sensitivity comprises: a) from about 0.1% to about 5% potassium nitrate; C1 from about 0.02% to about 2% SLS; from about 0.1% to about 20% by weight of an orally-acceptable polar surfactant, said surfactant comprising a hydrophobic portion selected from the group consisting of a (C 6 -C30) alkyl group and a polymeric silicone group; and an orally-acceptable aqueous vehicle; wherein the molar ratio of the surfactant of to SLS of is greater than or equal to about 1:1.
Another specific oral rinse of the present invention especially useful for removing or loosening plaque and/or stains from dental surfaces comprises: a) from about 0.1% to about 5% of a potassium salt selected from the group consisting of dipotassium pyrophosphate, tetrapotassium pyrophosphate, tripotassium pyrophosphate, monopotassium pyrophosphate, and combinations thereof; from about 0.02% to about 2% SLS; from about 0.1% to about 20% by weight of an orally-acceptable polar surfactant, said surfactant comprising a hydrophobic portion selected from the group consisting of a (C6-C30) alkyl group and a polymeric silicone group; and an orally-acceptable aqueous vehicle; wherein the molar ratio of the surfactant of to SLS of is greater than or equal to about 1:1.
Flavorings can also optionally be included in the compositions of the subject invention. The flavoring can comprise synthetic chemicals, purified chemicals, natural extracts, or combinations thereof. Examples of flavorings which can be used include, but are not limited to, peppermint; spearmint; wintergreen; clove; cinnamon; anise; sassafras; bubble gum; or fruit flavoring such as lemon, orange, lime, or cherry; or combinations thereof. An "amount of a flavoring effective to provide flavor to a composition", for purposes of this C"1 invention, means any amount at which the flavor of the flavoring can be tasted by a subject Ousing the oral composition comprising the flavoring. One of ordinary skill can determine an Z amount of a flavoring effective to provide flavor to a composition by using known techniques.
0Various factors known in the art, such as for example the type of flavoring, can be considered when determining the effective amount of any flavoring. Generally, the amount of flavoring that is effective ranges from about 0.001% to about 0.5% of a liquid composition according to _the subject invention, and from about 0.25% to about 5% of a paste or gel of the subject ~invention. Preferred amounts of a flavoring for a liquid range from about .01% to about 0.3% and for a paste or gel from about 0.5% to about Also provided by the present invention are oral compositions for reducing dental Snerve and/or dentin sensitivity which comprise particular flavorings, namely ones that do not (comprise a substantial amount of menthol. Such compositions are useful because they do not aggravate sensitive dental nerves and/or dentin as much as oral compositions for sensitive teeth and/or gums which comprise menthol-containing ingredients. In this aspect of the invention, the ingredient which possesses activity in reducing dental nerve and/or dentin sensitivity may be a potassium salt, for example potassium chloride, potassium nitrate, potassium bicarbonate, or another potassium salt noted above as having activity in reducing dental nerve and/or dentin sensitivity, or it may be one or more other substances capable of reducing dental nerve and/or dentin sensitivity, such as strontium chloride or another soluble salt of strontium, or a soluble stannus salt. Other substances which possess activity in reducing dental nerve and/or dentin sensitivity are known in the art and may be used in this aspect of the invention. The composition can comprise a combination of ingredients that each reduces dental nerve and/or dentin sensitivity. An "effective amount" of the ingredient which possesses activity in reducing dental nerve and/or dentin sensitivity, for example potassium chloride, potassium nitrate, and potassium bicarbonate, is any amount which is able to reduce dental nerve and/or dentin sensitivity when the composition is orally applied to a dental surface. Effective amounts of ingredients that reduce dental nerve and/or dentin sensitivity are known in the art and generally are in the range of from about 0.1% to about by weight of the composition. A preferred amount of an ingredient that reduces dental nerve and/or dentin sensitivity is from about 0.05% to about A flavoring that "does not contain a substantial amount of menthol", for purposes of the subject invention and unless otherwise indicated, is any flavoring that does not contain a sufficient amount of menthol to aggravate a sensitive dental nerve or sensitive dentin when used in an oral composition in an amount effective to provide flavor to the composition. A flavoring which does not contain a sufficient amount of menthol to aggravate a sensitive dental nerve or sensitive dentin can be determined by one of ordinary skill, for example by orally applying to a dental surface of a sensitive tooth a composition comprising an amount of a flavoring effective to provide flavor to the composition, and determining if the composition aggravates the sensitive nerve or dentin of the tooth, thereby determining if the flavoring z contains a sufficient amount of menthol to aggravate a sensitive dental nerve or sensitive dentin. Some flavorings are generally known in the art to contain no menthol, and such flavorings would therefore not have to be tested to determine if they can be used in the subject invention. Other flavorings can be prepared so as to not contain a substantial amount of menthol. Accordingly, the subject invention also provides a mint flavoring that does not comprise a substantial amount of menthol, said mint flavoring being either a dementholated Snatural mint extract or a synthetic blend. In one embodiment, a composition of the subject (-i invention for reducing dental nerve and/or dentin sensitivity comprises a flavoring which O contains from about 0 to about less than 0.05% menthol. Preferably the amount of menthol is less than about 0.01%.
Methods for obtaining flavorings are known in the art and any such method can be used to obtain a flavoring for the subject invention, provided the flavoring does not contain a substantial amount of menthol. For example, certain mints, peppermint are known to naturally comprise menthol, and therefore a peppermint flavoring must be either dementholated or synthesized by blending chemical components (excluding a substantial amount of menthol) in order to be useful for practicing this aspect of the subject invention.
In one embodiment, the flavoring in the sensitivity compositions of this invention does not contain a mint flavoring. Examples of flavoring that are not mint flavorings include, but are not limited to, clove; cinnamon; anise; sassafras; bubble gum; and fruit flavorings, such as, but not limited to, lemon, orange, lime, and cherry.
In another embodiment, however, the flavoring in the sensitivity compositions of the subject invention is a mint flavoring that does not comprise a substantial amount of menthol.
Such flavorings are preferred in the sensitivity compositions of the subject invention since many consumers prefer mint flavorings to other types of flavorings. Some mints, such as spearmint, naturally do not contain menthol. Peppermint however, as discussed above, comprises menthol. Any peppermint flavoring, including peppermint used in a mixture of flavorings (for example, a blend of spearmint plus peppermint), must either be dementholated or prepared by blending chemical components before use in this aspect of the subject invention.
The term "dementholated" means all or part of the menthol from a natural mint extract has been chemically removed. Methods of dementholation are known in the art and generally involve cooling the raw oil that is obtained from the mentha arvensis plant from a temperature of around 400C to just over 0°C for a period of from about ten to about fourteen days and separating the crystals formed during this period, which consist essentially of menthol, from the residual oil (see, Haarmann Reimer (Springfield, New Jersey), Optamint N Freshness with taste to match). Any natural mint (which naturally contains menthol, such as peppermint) used in accordance with the present invention so as not to unduly aggravate Z sensitive teeth must be sufficiently dementholated so as to not contain a substantial amount of menthol.
Preferably, however, mint, including peppermint, used in a composition of the subject invention for reducing dental nerve and/or dentin sensitivity is synthesized by blending _chemical components, excluding a substantial amount of menthol, i.e. it is a "synthetic blend".
i For purposes of this invention, the term "synthetic blend" refers to a flavoring prepared by blending chemical components. The synthetic blend can comprise synthetic chemical components, purified chemical components, or combinations thereof. A "synthetic chemical" for purposes of this invention, unless otherwise indicated, means a chemical that is i synthesized from non-natural sources. Synthetic chemicals can, however, be chemically the same as chemicals which are found in natural sources. A synthetic chemical can on the other hand be a molecule which is not found in nature. A "purified chemical" for purposes of this invention, unless otherwise indicated, is a chemical which has been substantially purified from a natural source such as a plant. Known methods of organic synthesis and purification can be used to obtain the synthetic and purified chemicals for the synthetic blends of the present invention. Blending of synthetic and purified chemicals to obtain flavorings which are synthetic blends is also known in the art.
A synthetic blend for use in the subject invention can possess a natural-like taste, for example a synthetic blend that has a peppermint taste; or it can possess a taste that does not occur in nature, for example a synthetic blend that has a wintergreen taste or an orange-mint taste. In general, synthetic blends, including mint flavoring which are synthetic blends, are more preferable than natural extracts for use as flavorings in the sensitivity compositions of the present invention.
As used herein, unless otherwise indicated, the terms "mint", "mint flavoring", and the like, refer to flavorings that have a mint taste, either a natural or natural-like mint taste such as a peppermint taste or spearmint taste, or a mint taste that does not naturally occur such as a wintergreen taste.
The orally-acceptable aqueous vehicle for the detergent compositions of the present invention can be, for example, water or a mixture of water and an orally-acceptable alcohol such as ethanol. An oral rinse of the present invention more specifically comprises from about 50% by weight to about 85% by weight of water based on the total weight of the composition, and, optionally, from about 5% to about 25% ethanol. Not all compositions of this invention, including oral rinses, comprise an alcohol however, and, in same cases, such as in compositions for reducing dental nerve and/or dentin sensitivity, absence of alcohol is preferred.
-16- C In certain compositions of the invention, especially those containing no alcohol or a O low alcohol content, it may be desirable to include preservatives, for example benzoic acid, Z sodium benzoate, methylparaben, propylparaben, sorbic acid, potassium sorbate, or combinations thereof. Other preservatives known in the art to be useful in detergent compositions can be used in the compositions of the present invention. The amount of preservative is generally within the range of from about 0% to about and preferably from about 0.01% to about 1%.
Examples of abrasives useful in dentifrices of the subject invention include, but are Snot limited to, abrasive silica such as precipitated silica or silica gels preferably having an z 10 average particle size ranging from about 0.1 to about 50 microns. Preferred silica abrasives include those marketed under the tradename SYLODENTTM or SYLOID T by the W. R. Grace Co. and those marketed under the tradename ZEODENTT by the J. M. Huber Corp. Other suitable abrasives include, but are not limited to, p-phase calcium pyrophosphate, alumina and calcium carbonate. Other abrasives can be used in the present invention. The amount of abrasive in a dentifrice composition ranges up to about 60% by weight, preferably from 10% by weight to 40% by weight.
Oral compositions of the present invention can optionally comprise humectants, which can impart a moist feeling to the mouth and, in some cases, can sweeten the compositions. Humectants useful in the oral compositions of the present invention include, but are not limited to, edible polyhydric alcohols such as glycerin, sorbitol, propylene glycol, xylitol, and cyclodextrins, including their derivatives. Other humectants known in the art can be used in the compositions of this invention. A humectant generally is present in an amount of from about 0.1% to about 30% for oral rinses and from about 10% to about 50% for dentifrices. If a humectant is included in an oral rinse of this invention, it is preferably present in an amount of from about 5% to about The oral compositions of the present invention can further comprise an effective amount of a soluble fluoride salt, for example sodium fluoride, potassium fluoride, or stannous fluoride; or a soluble monofluorophosphate salt such as sodium monofluorophosphate. An effective amount of a soluble fluoride salt or soluble sodium monofluorophosphate salt for a composition of the present invention is an amount that is effective in preventing cavities, generally an amount sufficient to provide from about 50 ppm to about 2,500 ppm fluoride ion to the composition; determining such an effective amount is within the ordinary skill in the art.
"Preventing cavities" means treating the teeth so that they are less prone to cavity formation.
Compositions of this invention can also optionally comprise thickening agents and/or binders. Typical thickening agents include, but are not limited to, xanthan gum, carrageenan, carboxyvinyl polymers, carbomers, cellulose gums such as carboxymethyl cellulose, cellulose derivatives such as hydroxyethylcellulose and silicas. Thickeners are usually present in the -17compositions in an amount of up to about 20%. Xanthan gum is a preferred thickener for an oral rinse. In dentifrices, silica-based thickeners, such as SYLOX T M Grace Co., Boca Raton, FL), can be used.
Examples of sweeteners that can optionally be included in the compositions of the present invention include, but are not limited to, saccharin, lactose, maltose, aspartame, acesulfame potassium (Nutrinova (Somerset, New Jersey, USA), sodium cyclamate, and polydextrose.
Coloring agents, including those acceptable for oral use, known in the art can also be used in the compositions of the present invention. Generally, a coloring agent is present in a composition of this invention in an amount of up to about 0.01%.
The compositions of the present invention can optionally contain other ingredients, for example fragrances, known in the art to be useful in detergent compositions for use in healthcare or as surface or fabric cleaners.
The stability of the detergent compositions of the present invention at low temperatures can be determined by cooling a composition to about 35'F, storing the composition at such temperature for about seven days, and then evaluating the composition for the presence or absence of any precipitate, such as crystals or flocculated material, after warming the cooled composition to a temperature of about room temperature. The stability of the compositions of the invention over time at room temperature can also be evaluated according to the above criterion, absence of precipitate, such as crystals or flocculated material.
The following examples are provided to merely illustrate aspects of the subject invention. They are not intended to, and should not be construed to, limit the invention set forth in the claims and more fully described herein.
Example 1 Eight surfactants were formulated into oral rinses (Formulations A-H) according to the present invention, as indicated in the following Table 1. The amounts of ingredients in Table 1 are weight percent, based on the total weight of the formulation. "TKPP" is tetrapotassium pyrophosphate, and"TSPP" is tetrasodium pyrophosphate; thus, each 1% by weight of the pyrophosphate anion P 2 0 7 4 75% of which is TKPP.
formulation contains Table 1 Ingredient A B C D E F G H Part A: Water 60.00 60.00 60.00 60.00 60.00 60.00 60.00 60.00 Xanthan 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 Gum TKPP 1.42 1.42 1.42 1.42 1.42 1.42 1.42 1.42 TSPP 0.38 0.38 0.38 0.38 0.38 0.38 0.38 0.38 Benzoic 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53 Acid Poloxomar 0.30 0.30 0.30 0.30 0.30 0.30 0.30 0.30 407 Na 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37 Benzoate Na 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 Saccharin Sorbitol 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 Part B: Water 7.0 7.0 7.0 7.0 7.0 7.0 7.0 Alcohol 7.0 7.0 7.0 7.0 7.0 7.0 7.0 (190 pf) SLS 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 surfactant* 1.5 1.5 1.5 1.0 1.0 1.0 0.75 flavoring 0.18 0.18 0.18 0.15 0.15 0.15 0.18 0.18 water qs qs Qs qs qs qs qs qs Total 100 100 100 100 100 100 100 100 -19- C£ *The surfactant used in each formulation was: >Formulation A, HAMPOSYL L-30 (Sodium Lauroyl Sarcosinate); z Formulation B, EMSORB 2726 (PEG 40 Sorbitan Diisostearate); Formulation C, Betaine ZF (CocamidopropylBetaine/Cocamidopropyl); Formulation D, PECOSIL DCT (SodiumDimethiconeCopolyolAcetyl/MethylTaurate); Formulation E, PECOSIL SM-40 (Dimethicone Copolyol Myristyl Ammonium Chloride); Formulation F, PECOSIL PS-100 (Dimethicone Copolyolphosphate); C Formulation G, TAURANOL WS (Ethanesulfonic acid, 2 0(methylamino)-N-Cocoacyl); and Formulation H, LIPOPEG 6000DS (PEG-150 Distearate).
£c Formulations A-H were prepared in general according to the following procedure: Part A was first prepared: Xanthan gum was dispersed in 60 wt% water and mixed for 15 minutes under high shear. The tetrapotassium pyrophospate, tetrasodium pyrophosphate, and benzoic acid were added to the Xanthan gum dispersion and the resulting mixture mixed for 15 minutes or until dissolved. The Poloxamer 407, sodium benzoate, sodium saccharin, and sorbitol were added, and the resulting mixture was then mixed; the resulting Part A was then mixed for 20 minutes.
Part B was prepared next: The sodium lauryl sulfate was dissolved in alcohol and 7 wt% water; this mixture was then mixed for 15 minutes or until the SLS dissolved. The surfactant* was added and the resulting mixture mixed for 10 minutes. The flavor was added and the resulting mixture then mixed for 10 minutes. The remaining water was added, and the resulting Part B mixed for 10 minutes.
Part B was slowly added to Part A and the resulting mixture mixed for 20 minutes.
The pH of each finished formulation was in the range of about 7.0 to about The above Formulations A-H were still clear after approximately one year or more at room temperature.
ri Example 2 SThe following Formulation I is one example of an oral rinse for reducing dental nerve Z and/or dentin sensitivity according to the subject invention. The pH of Formulation I is within the range of from about 5.0 to about Formulation I Ingredient wt./wt.% r Water 60.010 Xanthan Gum 0.035 Potassium Nitrate 1.000 HAMPOSYLTM L-30 2.000 c Sodium Saccharin 0.030 Sorbitol 20.000 Aloe powder 0.250 Sodium salicylate 2.000 Disodium Phosphate 0.025 Monosodium Phosphate 0.100 Alcohol (190 pf) 7.000 Water 7.000 SLS 0.400 Flavoring 0.150 100.000% Formulation I was prepared by as follows: The xanthan gum was dispersed in 60.010 wt% water and mixed for 15 minutes under high shear. The KNO 3 was added and mixed until dissolved. Hamposyl L-30, sodium saccharin, sorbitol, aloe powder, and sodium salicylate were added; the resulting mixture was mixed for 20 minutes. The disodium phosphate and monosodium phosphate were added; the resulting mixture was then mixed for 10 minutes. In a separate container, the alcohol, 7.0 wt% water, SLS, and flavor were combined until the SLS dissolved. The alcohollwater/SLS/ flavor mixture was added to the batch and mixed for minutes.
Cl Example 3 SThe following Formulation J is one example of a dentifrice according to the subject Z invention, in the form of a liquid gel, for reducing dental nerve and/or dentin sensitivity: Formulation J Ingredient wt./wt. Hydroxy EthylCellulose 1.000% SPEG-8 3.000 Glycerin 99.5%) 10.000 Purified Water 18.000 Potassium Nitrate 5.000 SSodium Fluoride 0.243 HAMPOSYLTM L-30 4.000 Xanthan Gum 0.300 Sorbitol 35.451 Sodium Saccharin 0.500
SYLODENT
T M 15 (thickening 8.000 silica from W.R. Grace Co.) SYLODENTTM 750 (abrasive silica 10.000 from W. R. Grace Co.) Dye(s) 0.006 SLS (30% solution) 3.000 Flavoring 1.500 100.000% Formulation J was prepared as follows: The carboxyethyl cellulose was dispersed in the PEG-8 and glycerin using a mixer. In a separate container, the KNO 3 was dissolved in the water and sorbitol and mixed until dissolved. NaF was added to the water mixture and mixing was continued for 25 minutes. The water/sorbitol/KNO3/NaF phase was added to the caroboxyethyl cellulose/PEG-8/glycerin mixture and mixed for 10 minutes. The xanthan gum was slowly added and mixed under high shear for 15 minutes. Hamposyl L-30, sodium saccharin, Sylodent 15, Sylodent 750, dyes (FD&C Blue #1 and D&C Yellow #10) were added; this resulting mixture was mixed until homogenous. The flavor was dissolved in the SLS and mixed for 5 minutes. The flavor/SLS mixture was added to the batch and mixed for minutes. The resulting gel was deaerated to remove entrapped air bubbles.
Claims (4)
1. An oral mouthrinse composition for reducing nerve sensitivity comprising: a) from about 0.01% by weight to about 5% by weight of an orally-acceptable, 00 soluble potassium salt; b) from about 0.01% by weight to about 10% by weight of a sodium (C 8 -C 24 alkylsulfate; Sc) from about 0.01% by weight to about 20% by weight of an orally-acceptable polar surfactant, said surfactant selected from the group consisting of (C 6 -C 30 fatty acid Smono or diester of ethoxylated sorbitan, a (C 6 -C 30 fatty acid diester of polyethylene glycol, a sodium salt of a (C 6 -C 30 fatty acyl sarcosinate, a (C 6 -C 3 0 fatty acyl ester of Ssarcosine acid, a sodium salt of a (C 6 -C 3 o) fatty acyl taurate, a sodium salt of a (C 6 -C 3 0 fatty acyl methyltaurate, a (C 6 -C 30 fatty acyl ester of taurine, a (C 6 -C 30 fatty acyl ester of methyltaurine acid, a (C 6 -C 3 0 fatty acyl betaine, a (C 6 -C 30 fatty acyl quaternary ammonium chloride, dimethicone copolyols, polydimethylsiloxane phosphate esters, polydimethylsiloxane copolyol phosphate esters, polydimethylsiloxane phosphobetaines, polydimethylsiloxane copolyol phosphobetaines, polydimethylsiloxane taurates, polydimethylsiloxane copolyol taurates, acetylated polydimethylsiloxane copolyols, and polydimethylsiloxane quaternium compounds, polydimethylsiloxane copolyol quaternium compounds; and d) an orally-acceptable aqueous vehicle comprising from about 50% to about water; wherein the potassium salt is dissolved in the composition and wherein the molar ratio of the surfactant of to the sodium (C 8 -C 2 4 alkylsulfate is greater than or equal to about 1:1 such that when are dissolved in the resultant composition is clear.
2. The oral mouthrinse composition according to claim 1, wherein the soluble potassium salt of the composition comprises a potassium pyrophosphate salt in an amount effective, optionally in combination with other pyrophosphate salts, to remove or loosen plaque and/or stains when the composition is orally applied to a dental surface.
3. The oral mouthrinse composition according to claim 1, wherein the soluble potassium salt of the composition comprises soluble potassium salt that possesses activity in reducing dental nerve and/or dentin sensitivity in an amount effective to reduce dental nerve and/or dentin sensitivity when the composition is orally applied to a dental surface.
4. The oral mouthrinse composition according to claim 3, wherein the soluble potassium salt that possesses activity in reducing dental nerve and/or dentin sensitivity is potassium nitrate.
677659-Ihjg The oral mouthrinse composition according to claim 3 or 4, further comprising a flavouring that does not comprise a substantial amount of menthol. 6. The oral mouthrinse composition according to claim 5, wherein the flavouring 00 that does not comprise a substantial amount of menthol is a mint flavouring. s 7. The oral mouthrinse composition according to any one of claims 1 to 6, wherein the soluble potassium salt is selected from the group consisting of a potassium pyrophosphate salt, potassium nitrate, and mixtures thereof. 8. An oral composition in the form of a rinse for reducing dental nerve and/or Sdentin sensitivity comprising from about 0.1% to about 5% potassium nitrate; from 0o about 0.02% to about 2% SLS; from about 0.1% to about 20% by weight of an orally- C acceptable polar surfactant, said surfactant selected from the group consisting of a (C 6 fatty acid mono diester of ethoxylated sorbitan, a (C 6 -C 30 fatty acid diester of polyethylene glycol, a sodium salt of a (C 6 -C 30 fatty acyl sarcosinate, a (C 6 -C 30 fatty acyl ester of sarcosine acid, a sodium salt of a (C 6 -C 3 0 fatty acyl taurate, a sodium salt of a (C 6 -C 3 0 fatty acyl methyltaurate, a (C 6 -C 30 fatty acyl ester of taurine, a (C 6 -C 30 fatty acyl ester of methyltaurine acid, a (C 6 -C 30 fatty acyl betaine, a (C 6 -C 30 fatty quaternary ammonium chloride, dimethicone copolyols, polydimethylsiloxane phosphate esters, polydimethylsiloxane copolyol phosphate esters, polydimethylsiloxane phosphobetaines, polydimethylsiloxane, copolyol phosphobetaines, polydimethylsiloxane taurates, polydimethylsiloxane copolyol taurates, acetylated polydimethylsiloxane copolyols, and polydimethylsiloxane quaternium compounds, polydimethylsiloxane copolyol quaterium compounds; and an orally-acceptable aqueous vehicle comprising from about 50% to about 85% water; wherein the potassium salt is dissolved in the composition and wherein the molar ratio of the surfactant of to the sodium (C8-C 2 4 alkylsulfate is greater than or equal to about 1:1 such that when are dissolved in the resultant composition is clear. 9. An oral composition in the form of a rinse for removing or loosening plaque and/or stains from dental surfaces comprising from about 0.1% to about 5% of a potassium salt selected from the group consisting of dipotassium pyrophosphate, tetrapotassium pyrophosphate, tripotassium pyrophosphate, monopotassium pyrophosphate, and combinations thereof; from about 0.02% to about 2% SLS; (c) from about 0.1% to about 20% by weight of an orally-acceptable polar surfactant, said surfactant selected from the group consisting of a (C 6 -C 30 fatty acid mono or diester of ethoxylate sorbitan, a (C 6 -C 30 fatty acid diester of polyethylene glycol, a sodium salt of a (C 6 -C 30 fatty acyl sarcosinate, a (C 6 -C 3 0) fatty acyl ester of sarcosine acid, a sodium salt 677659-1hjg Sof a (C 6 -C 30 fatty acyl taurate, a sodium salt of a (C 6 -C 30 fatty acyl methyltaurate, a (C 6 SC 30 fatty acyl ester of taurine, a (C 6 -C 30 fatty acyl ester of methyltaurine acid, a (C 6 -C 3 0 Sfatty acyl betaine, a (C 6 -C 30 fatty acyl quaternary ammonium chloride, dimethicone 00 copolyols, polydimethylsiloxane phosphate esters, polydimethylsiloxane copolyol phosphate esters, polydimethylsiloxane phosphobetaines, polydimethylsiloxane copolyol Sphosphobetaines, polydimethylsiloxane taurates, polydimethylsiloxane copolyol taurates, acetylated polydimethylsiloxane copolyols, and polydimethylsiloxane quatemium Scompounds, polydimethylsiloxane copolyol quaternium compounds; and an orally- Sacceptable aqueous vehicle comprising from about 50% to about 85% water; wherein the 0o potassium salt is dissolved in the composition and wherein the molar ratio of the C surfactant of to the sodium (Cs-C 24 alkylsulfate is greater than or equal to about 1:1 such that when and are dissolved in the resultant composition is clear. An oral composition as claimed in claim 1, 8 or 9, substantially as hereinbefore described with reference to any one of the examples. 11. A method of preparing an oral composition as claimed in claim 1, 8 or 9, said method substantially as hereinbefore described with reference to any one of the examples. 12. An oral composition prepared by the method of claim 11. Dated 27 February 2007 Pfizer Products Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON 677659-1 hjg
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004231211A AU2004231211B2 (en) | 1999-03-12 | 2004-11-19 | Compositions comprising a potassium salt active ingredient, including oral compositions for reducing dental nerve and dentin sensitivity comprising a non-menthol flavoring |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60124258 | 1999-03-12 | ||
| AU20807/00A AU2080700A (en) | 1999-03-12 | 2000-03-10 | Compositions comprising a potassium salt active ingredient, including oral compositions for reducing dental nerve and dentin sensitivity comprising a non-menthol flavoring |
| AU2004231211A AU2004231211B2 (en) | 1999-03-12 | 2004-11-19 | Compositions comprising a potassium salt active ingredient, including oral compositions for reducing dental nerve and dentin sensitivity comprising a non-menthol flavoring |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU20807/00A Division AU2080700A (en) | 1999-03-12 | 2000-03-10 | Compositions comprising a potassium salt active ingredient, including oral compositions for reducing dental nerve and dentin sensitivity comprising a non-menthol flavoring |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2004231211A1 AU2004231211A1 (en) | 2004-12-23 |
| AU2004231211B2 true AU2004231211B2 (en) | 2007-03-29 |
Family
ID=34382416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004231211A Expired AU2004231211B2 (en) | 1999-03-12 | 2004-11-19 | Compositions comprising a potassium salt active ingredient, including oral compositions for reducing dental nerve and dentin sensitivity comprising a non-menthol flavoring |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2004231211B2 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993004663A1 (en) * | 1991-08-30 | 1993-03-18 | Church & Dwight Company, Inc. | Anticalculus dentifrices |
-
2004
- 2004-11-19 AU AU2004231211A patent/AU2004231211B2/en not_active Expired
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993004663A1 (en) * | 1991-08-30 | 1993-03-18 | Church & Dwight Company, Inc. | Anticalculus dentifrices |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004231211A1 (en) | 2004-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7435409B2 (en) | Compositions comprising a potassium salt active ingredient, including oral compositions for reducing dental nerve and dentin sensitivity comprising a non-menthol flavoring | |
| RU2628540C2 (en) | Oral care products, including zinc oxide and trimethylglycine | |
| AU2022283265A1 (en) | Oral care compositions | |
| JP3142543B2 (en) | How to remineralize teeth | |
| AU2015419238B2 (en) | Oral care product and methods of use and manufacture thereof | |
| JPH10501265A (en) | Mouth rinse composition | |
| AU2022378558A1 (en) | Oral care compositions | |
| JP3241922B2 (en) | Oral composition | |
| AU2004231211B2 (en) | Compositions comprising a potassium salt active ingredient, including oral compositions for reducing dental nerve and dentin sensitivity comprising a non-menthol flavoring | |
| AU2020337430B2 (en) | Zinc phosphate containing compositions | |
| CA2434740C (en) | Aqueous detergent composition comprising a soluble potassium salt, a sodium alkylsulfate and a polar surfactant | |
| JP2023178143A (en) | Oral composition | |
| CA2277664A1 (en) | Compositions comprising a potassium salt active ingredient, including oral compositions for reducing dental nerve and dentin sensitivity comprising a non-menthol flavoring | |
| JPH07206650A (en) | Oral composition | |
| CN117320683A (en) | Oral care composition | |
| AU2024342638A1 (en) | Oral care compositions comprising a whitening agent | |
| WO2023234379A1 (en) | Oral composition | |
| JPH07258052A (en) | Oral composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |